Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(alendronate)
6,116 results
  • Bisphosphonates for osteoporosis in people with cystic fibrosis. [Review]
    Cochrane Database Syst Rev. 2023 01 10; 1:CD002010.Jeffery TC, Chang AB, Conwell LS
  • CONCLUSIONS: Oral and intravenous bisphosphonates may increase bone mineral density in people with cystic fibrosis, but there are insufficient data to determine whether treatment reduces fractures. Severe bone pain and flu-like symptoms may occur with intravenous bisphosphonates. Before any firm conclusions can be drawn, trials in larger populations, including children, and of longer duration are needed to determine effects on fracture rate and survival. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids can ameliorate or prevent these adverse events. Future trials should also assess gastrointestinal adverse effects associated with oral bisphosphonates.
  • Antibacterial Effect of Some Eukaryotic Sterol Biosynthesis Inhibitors. [Journal Article]
    Adv Biomed Res. 2022; 11:90.Arjmand G, Haeri MR
  • CONCLUSIONS: Our results show that farnesyl pyrophosphate synthase and class II HMG-CoA reductases inhibitors (ketoconazole and simvastatin) have reasonable antibacterial activity against gram-positive bacteria. These two enzymes provide suitable targets for designing new antibiotics based on modifying the chemical structure of currently used drugs to obtain maximum activity.
New Search Next